中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (5): 340-344.doi: 10.19401/j.cnki.1007-3639.2017.05.004

• 论著 • 上一篇    下一篇

糖代谢中关键酶果糖双磷酸酶-1与卵巢癌化疗敏感性关系的研究

李浩然1,李梦娇1,刘 霏1,王子良2,程 玺1   

  1. 1. 复旦大学附属肿瘤医院妇瘤科,复旦大学上海医学院肿瘤学系,上海 200032 ;
    2. 复旦大学附属肿瘤医院肿瘤研究所,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2017-05-30 发布日期:2017-06-14
  • 通信作者: 程 玺 E-mail:cheng_xi1@hotmail.com
  • 基金资助:
    国家自然科学基金青年科学基金项目(NSFC1212)。

Research on the relationship between fructose-1, 6-bisphosphatase and chemosensitivity of ovarian carcinoma

LI Haoran1, LI Mengjiao1, LIU Fei1, WANG Ziliang2, CHENG Xi1   

  1. 1.Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Department of Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2017-05-30 Online:2017-06-14
  • Contact: CHENG Xi E-mail: cheng_xi1@hotmail.com

摘要: 背景与目的:上皮性卵巢癌是女性生殖系统恶性肿瘤中死亡率最高的肿瘤。化疗期间耐药的产生是卵巢癌死亡率高的主要原因。果糖双磷酸酶-1(fructose-1, 6-bisphosphatase,FBP1)是糖代谢过程中的关键酶。FBP1用于催化1,6 -二磷酸果糖水解为6-磷酸果糖和磷酸盐,从而抑制细胞的糖酵解。该研究旨在探讨FBP1与卵巢癌化疗敏感性关系。方法:采用免疫组织化学方法检测209例卵巢癌患者标本中FBP1蛋白的表达水平及其与卵巢癌患者化疗敏感性的关系。结果:在209例卵巢癌组织中,FBP1的阳性表达率为49.3%(103/209),FBP1表达阳性组患者生存期长于阴性组,二者之间差异有统计学意义(42.6个月 vs 62.1个月,P=0.003),并且FBP1表达与化疗敏感性相关(P=0.007)。结论:糖代谢中关键酶基因FBP1的表达可能与卵巢癌对化疗的敏感性有关,可作为化疗敏感性及预后判断的重要指标。

关键词: 果糖双磷酸酶-1, 卵巢癌, 顺铂, 化疗敏感性

Abstract: Background and purpose: Epithelial ovarian carcinoma is the most malignant tumor in female reproductive system because of its resistance to chemotherapy. Fructose-1, 6-bisphosphatase (FBP1) is a rate-limiting enzyme in gluconeogenesis used to catalyze the hydrolysis of fructose-1, 6-bisphosphate to fructose-6-phosphate and inorganic phosphate, thereby inhibiting the effect of glycolysis in tumor cells. This study aimed to investigate the association between the expression of FBP1 and chemosensitivity. Methods: The expression level of FBP1 in ovarian cancer patients was measured by immunohistochemistry. Results: According to the results of immunohistochemistry in 209 ovarian carcinoma specimens, the percentage of positive FBP1 expression was about 49.3% (103/209). Loss of FBP1 was a negative factor of survival (42.6 months vs 62.1 months, P=0.003). Besides, patients who were sensitive to chemotherapy displayed significantly higher scores of FBP1 expression than patients who were resistant to therapy (P=0.007). Conclusion: The rate-limiting enzyme FBP1 in gluconeogenesis can be used as a biomarker for predicting the chemoresistance and prognosis of ovarian cancer patients.

Key words: Fructose-1, 6-bisphosphatase, Ovarian neoplasms, Cisplatin, Chemosensitivity